Read the full article at: https://oncdata.com/ai-driven-pathological-subtyping-pancreatic-cancer-ashish-manne

Artificial intelligence (AI) continues to generate excitement across oncology, but its real-world clinical impact remains uneven. In this episode of Exploring AI in Oncology, Dr. Ashish Manne, a Gastrointestinal Medical Oncologist at The Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, shares his American Association for Cancer Research (AACR) presentation on AI-driven pathological subtyping in pancreatic cancer and highlights a critical shift: moving AI from theoretical promise to practical application.

Think PFIC is only a pediatric disease? Think again.

Progressive Familial Intrahepatic Cholestasis (PFIC) was long considered a condition exclusive to children. However, breakthroughs in genomic sequencing are revealing a hidden population: adults with "unexplained" cholestasis who are actually living with undiagnosed PFIC variants. Early identification is the difference between manageable care and irreversible liver damage.

In this interview episode Dr. Aparna Goel, Stanford School of Medicine, and Dr. Laura Bull, UC San Francisco, break down the adult phenotype of PFIC and how clinicians can close the diagnostic gap.

What You'll Hear In This Episode:

The Adult Phenotype: Why adult cases often present as "indolent" or mild compared to the severe jaundice seen in infants.

Diagnostic Red Flags: When to move beyond standard autoimmune panels and look for genetic markers.

Genetic Testing 101: A comparison of targeted gene panels vs. whole exome sequencing for the most efficient diagnosis.

The Power of a Name: How a specific PFIC diagnosis changes everything—from family counseling to starting life-altering IBAT inhibitors.

💡 Earn 1.5 Free CME/AAPA Credits

👉 Join the Escape Room: i3health.com/pfic

Melanoma treatment is changing rapidly, with immunotherapy and targeted therapies improving outcomes across multiple care settings. In this expiring CME podcast, Michael A. Davies, MD, PhD, University of Texas, MD Anderson Cancer Center, shares practical, evidence-driven insights on biomarkers, combination therapies, and treatment sequencing to help clinicians personalize care and stay current with the latest advances.

Listen before the activity expires on Wednesday, April 29!

Module 1: bit.ly/4iYmYD2

Claim CME/NCPD credit: bit.ly/44yO9RB

To view/download the slide deck from Module 1: bit.ly/3OHSZq8

To view/download the slide deck from Module 2: bit.ly/4vVm2qL

Melanoma care is evolving fast—and staying current can directly impact patient outcomes. In this expiring CME podcast, Michael A. Davies, MD, PhD, The University of Texas, MD Anderson Cancer Center, breaks down how today’s treatment strategies are reshaping care across the neoadjuvant, adjuvant, and metastatic settings.

With melanoma accounting for more than 100,000 new cases and 8,000 deaths each year in the United States, module 1 explores the evidence behind the growing role of immunotherapy, targeted therapies, predictive biomarkers, combination approaches, and personalized treatment selection and sequencing.

Listen now before this episode expires on Wednesday, April 29.

To continue the series, listen to Module 2: bit.ly/44yO9RB

To claim CME/NCPD credit: bit.ly/4iYmYD2

To view/download the slide deck from Module 1: bit.ly/3OHSZq8

To view/download the slide deck from Module 2: bit.ly/4vVm2qL

Read the full article at: https://oncdata.com/exploring-ai-helioliver

Patients diagnosed with early-stage liver cancer have a significantly higher survival rate compared to those diagnosed in later stages, yet screening options and barriers persist. In the latest episode of Exploring AI in Oncology, Waqas Haque, MD, MPH, speaks with Bharat Tewarie, MD, MBA, the CEO of Helio Genomics, about the company’s AI-powered blood test, HelioLiver, and its potential role in detecting hepatocellular carcinoma (HCC), the most common form of liver cancer. Dr. Tewarie shares why liver cancer is a strong use case for blood-based early detection, how HelioLiver may fit into existing workflows, and barriers to overcome for broader adoption.

The treatment of esophagogastric cancer is undergoing a profound transformation. In this episode, Yelena Janjigian, MD (MSKCC), discusses how perioperative chemoimmunotherapy and precision biomarkers are redefining the standard of care.

Key highlights include:

- The Perioperative Shift: Why starting immunotherapy before surgery is achieving unprecedented pathologic responses.

- Precision Testing: The essential role of MSI, PD-L1, HER2, and CLDN18.2 testing for every patient.

- Avoiding Understaging: Why clinical evaluation must go beyond imaging to prevent missed therapeutic opportunities.

- Multidisciplinary Success: The critical need for surgeon-oncologist communication before the first incision.

Tune in to learn why "cure" is the new benchmark in localized disease and how to integrate these advances into your clinical practice today.

Interested in the complete CE activity?

Complete Module 1: https://bit.ly/45u106o

Complete Module 2: https://bit.ly/3HtOziO

Click here to view the full CME/NCPD/CPE/AAPA activity and hear additional insights on the HER2-mutant NSCLC treatment landscape!

https://i3health.com/course-information/nsclc-advances

The FDA’s recent expanded approval of zongertinib marks a significant milestone in the treatment of non-small cell lung cancer (NSCLC). As the first oral human epidermal growth factor receptor 2 (HER2) inhibitor to move into the frontline setting, this therapy offers a new standard of care for patients with metastatic or unresectable non-squamous NSCLC harboring HER2 mutations. Following the approval, Beth Sandy, Thoracic Oncology Nurse Practitioner at the University of Pennsylvania, sat down to explore its clinical implications, including efficacy data, side effect management, and the potential of having a once-daily oral pill for improving patient experiences.

Choosing Not to Treat: How Do You Know When the Best Treatment Is No Treatment? by i3 Health

Stay ahead in Systemic Mastocytosis (SM) treatment! This interview, featuring Dr. Mariana Castells, explores the latest advancements in patient-centered care, including new drug approvals, multidisciplinary approaches, and crucial diagnostic updates. Learn how to shorten diagnosis times and improve long-term patient quality of life.

Don't forget to take the activity and claim your credit after the episode!

Click here to take module 1 of the activity: bit.ly/3Y3ivHM

Hemophilia care is evolving faster than ever. Dr. Robert Sidonio, Jr., a leading expert from Children’s Healthcare of Atlanta, joins us to discuss the latest breakthroughs in research and clinical trials. From navigating new treatment options to the importance of personalized patient selection, Dr. Sidonio shares the "real-world" perspective clinicians need to stay ahead.

Listen now to discover what the future holds for hemophilia management!

Click here to complete the activity, Raising the Bar for Hemophilia Management, and claim your CME credit: https://bit.ly/3Ini6vj